Last reviewed · How we verify

Letrozole or Anastrozole Tablets

Jiangsu HengRui Medicine Co., Ltd. · Phase 3 active Small molecule

Letrozole or Anastrozole Tablets is a Aromatase inhibitor Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 3 development for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.

Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.

Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.

At a glance

Generic nameLetrozole or Anastrozole Tablets
SponsorJiangsu HengRui Medicine Co., Ltd.
Drug classAromatase inhibitor
TargetAromatase (CYP19A1)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Both drugs inhibit the aromatase enzyme, which catalyzes the final step of estrogen synthesis in postmenopausal women. By depleting circulating estrogen levels, they suppress the growth of estrogen-dependent breast cancer cells. These are non-steroidal aromatase inhibitors commonly used as first-line endocrine therapy for hormone receptor-positive breast cancer.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Letrozole or Anastrozole Tablets

What is Letrozole or Anastrozole Tablets?

Letrozole or Anastrozole Tablets is a Aromatase inhibitor drug developed by Jiangsu HengRui Medicine Co., Ltd., indicated for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.

How does Letrozole or Anastrozole Tablets work?

Letrozole and Anastrozole are aromatase inhibitors that block the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.

What is Letrozole or Anastrozole Tablets used for?

Letrozole or Anastrozole Tablets is indicated for Hormone receptor-positive, HER2-negative breast cancer in postmenopausal women (adjuvant or metastatic), Extended adjuvant therapy following tamoxifen in postmenopausal women with early-stage breast cancer.

Who makes Letrozole or Anastrozole Tablets?

Letrozole or Anastrozole Tablets is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).

What drug class is Letrozole or Anastrozole Tablets in?

Letrozole or Anastrozole Tablets belongs to the Aromatase inhibitor class. See all Aromatase inhibitor drugs at /class/aromatase-inhibitor.

What development phase is Letrozole or Anastrozole Tablets in?

Letrozole or Anastrozole Tablets is in Phase 3.

What are the side effects of Letrozole or Anastrozole Tablets?

Common side effects of Letrozole or Anastrozole Tablets include Hot flashes, Arthralgia/joint pain, Fatigue, Headache, Nausea, Osteoporosis/bone loss.

What does Letrozole or Anastrozole Tablets target?

Letrozole or Anastrozole Tablets targets Aromatase (CYP19A1) and is a Aromatase inhibitor.

Related